JULIANNE TOMAC: Open Payments
NPI 1245018944 · O FALLON, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,298 in 123 payments from 35 companies in 2025. Trend: 2023 $137 · 2024 $1,326 · 2025 $3,298
Food & beverage: $2,419Long term medical supply or device loan: $698Education: $181
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 21 | $1,033 |
| Janssen Biotech, Inc. | 13 | $297 |
| Merck Sharp & Dohme LLC | 9 | $173 |
| ABBVIE INC. | 7 | $137 |
| Incyte Corporation | 7 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $123 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $115 |
| SEAGEN INC. | 1 | $95 |
| Eisai Inc. | 4 | $95 |
| EMD Serono, Inc. | 3 | $80 |
Products named: KISQALI, RYBREVANT, KEYTRUDA, Fabhalta, Nubeqa, Lenvima, ULTOMIRIS, JAKAFI.
Industry payments across IL — which companies pay providers there.
